Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption

NCT00672191 is registered in ClinicalTrials.gov with Argos Therapeutics as lead sponsor.

NCT NCT00672191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00672191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption
Lead sponsor
Argos Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
November 30, 2011
Enrollment
59 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections